Clinical and Microbiological Characteristics of Proven Invasive Aspergillosis Due to Rare/Cryptic Species in Allogeneic Hematopoietic Stem Cell Transplant Recipients.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
18 01 2022
Historique:
pubmed: 16 11 2021
medline: 23 3 2022
entrez: 15 11 2021
Statut: ppublish

Résumé

There are few reports on the clinical course of proven invasive aspergillosis (IA) due to rare/cryptic species in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. We retrospectively reviewed the electronic medical records of patients who underwent allo-HSCT between January 2012 and December 2018. Of 934 allo-HSCT recipients, 10 were diagnosed with proven IA and 61 were diagnosed with probable IA. DNA sequencing was performed in cases of proven IA, and Aspergillus could be identified to the species level in 8 of the 10 cases. Three were due to A. fumigatus, and 5 were due to rare/cryptic Aspergillus species, namely,

Identifiants

pubmed: 34780271
doi: 10.1128/AAC.01630-21
pmc: PMC8765323
doi:

Substances chimiques

Antifungal Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0163021

Références

J Clin Microbiol. 2008 Aug;46(8):2568-72
pubmed: 18562581
Antimicrob Agents Chemother. 2013 Jul;57(7):3380-7
pubmed: 23669377
Clin Infect Dis. 2019 Apr 24;68(9):1463-1471
pubmed: 30307492
Int J Infect Dis. 2013 Feb;17(2):e101-9
pubmed: 23084969
Med Mycol. 2018 Jun 1;56(4):501-505
pubmed: 28992138
J Clin Oncol. 2018 Oct 20;36(30):3043-3054
pubmed: 30179565
J Infect Chemother. 2019 Apr;25(4):307-310
pubmed: 30503017
Eukaryot Cell. 2005 Mar;4(3):625-32
pubmed: 15755924
J Antimicrob Chemother. 2010 Oct;65(10):2116-8
pubmed: 20729241
Mycopathologia. 2014 Dec;178(5-6):427-33
pubmed: 24972670
J Clin Microbiol. 2014 Oct;52(10):3633-40
pubmed: 25078909
Front Microbiol. 2018 Jul 23;9:1656
pubmed: 30083151
Stud Mycol. 2020 Jun 27;95:5-169
pubmed: 32855739
Clin Infect Dis. 2010 Apr 15;50(8):1091-100
pubmed: 20218877
Antimicrob Agents Chemother. 2012 Jan;56(1):584-7
pubmed: 22024829
Chest. 2004 Dec;126(6):1783-8
pubmed: 15596674
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
J Clin Microbiol. 2009 Oct;47(10):3138-41
pubmed: 19675215
J Clin Microbiol. 2019 Jun 25;57(7):
pubmed: 31018982
Blood. 2005 Oct 15;106(8):2641-5
pubmed: 15998833
Emerg Infect Dis. 2014 Sep;20(9):1498-503
pubmed: 25148217
Antimicrob Agents Chemother. 2010 Nov;54(11):4545-9
pubmed: 20805399
Mycoses. 2020 Dec;63(12):1283-1298
pubmed: 32918365

Auteurs

Ryosuke Yamamuro (R)

Department of Infectious Diseases, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Muneyoshi Kimura (M)

Department of Infectious Diseases, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Yuki Asano-Mori (Y)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Masahiro Abe (M)

Department of Fungal Infection, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.

Shigeki Nakamura (S)

Department of Fungal Infection, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.

Takashi Umeyama (T)

Department of Fungal Infection, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.

Satoshi Yamagoe (S)

Department of Fungal Infection, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.

Yoshitsugu Miyazaki (Y)

Department of Fungal Infection, National Institute of Infectious Diseasesgrid.410795.e, Tokyo, Japan.

Sho Ogura (S)

Department of Infectious Diseases, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Takashi Sakoh (T)

Department of Infectious Diseases, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Takashi Mitsuki (T)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Kyosuke Yamaguchi (K)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Mitsuhiro Yuasa (M)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Daisuke Kaji (D)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Kosei Kageyama (K)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Aya Nishida (A)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Yuki Taya (Y)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Kazuya Ishiwata (K)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Shinsuke Takagi (S)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Hisashi Yamamoto (H)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Go Yamamoto (G)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.

Naoyuki Uchida (N)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Atsushi Wake (A)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Shuichi Taniguchi (S)

Department of Hematology, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Hideki Araoka (H)

Department of Infectious Diseases, Toranomon Hospitalgrid.410813.f, Tokyo, Japan.
Okinaka Memorial Institute for Medical Research, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH